Systematix

Institutional Equities

EMS 16 April 2025

4QFY25 RESULT PREVIEW

Industry

EMS

Sector Rating (Prices as of 15 April 2025)

Sector Rating (Frices as of 15 April 2025)									
Company (Bloomberg Code)	TP (Rs)	Reco.							
Amber Enterprises (AMBER)	8,052	BUY							
Avalon Technologies (AVALON)	827	HOLD							
Dixon Technologies (DIXON)	17,587	BUY							
Elin Electronics (ELIN)	167	BUY							
Kaynes Technology (KAYNES)	5,517	HOLD							
PG Electroplast (PGEL)	981	HOLD							
Syrma SGS Technology (SYRMA)	713	BUY							

Source: Systematix Institutional Research

Seasonal, structural tailwinds to drive growth

The seven companies under our coverage are expected to report robust revenue/EBITDA/PAT growth of 88%/79%/99% YoY in 4QFY25, respectively. This strong performance is likely to be driven by channel filling ahead of the summer season, aided by seasonal tailwinds. Growth momentum seems particularly strong in the room air conditioner (RAC) segment, while a healthy volume ramp-up is also expected in the mobiles category. EMS companies are expected to post solid growth, supported by strong order inflows and an increasing focus on local value addition, positioning them well for sustained growth. We prefer DIXON (BUY), KAYNES (HOLD), AMBER (BUY) and SYRMA (BUY) within our coverage universe.

Companies to report strong growth in 4QFY25

We expect companies within our coverage to report healthy 88%/79%/99% YoY growth in revenue/EBITDA/PAT, respectively. DIXON is expected to post the strongest topline growth of 159% YoY, driven by a surge in the mobiles segment, given the QoQ ramp-up in Ismartu volumes during the quarter. KAYNES is likely to deliver 67% YoY revenue growth, driven by execution of smart meter orders. AVALON is expected to clock revenue/EBITDA/PAT growth of 43%/129%/217% YoY, aided by recovery in its US business and onboarding of new clients. We expect SYRMA to record revenue growth of 29% YoY, with EBITDA margin slated to expand to 10.1%, as the contribution from the lower-margin consumer business declines as guided by the management. ELIN is set for a modest quarter with revenue/EBITDA growth estimated to rise by 12%/18% YoY, respectively.

Contract Manufacturers to ride the strong RAC demand

Channel checks indicate a ~25% YoY rise in primary RAC industry volumes in 4QFY25, despite a high base, a result of early channel stocking in anticipation of a hot summer. Companies focused on cooling products are expected to see solid growth. We estimate revenue/EBITDA/PAT growth of 54%/67%/113% YoY for PGEL and 24%/29%/48% YoY for AMBER, respectively.

Positive stance on EMS maintained:

We remain positive on the EMS sector, supported by strong structural tailwinds and policy initiatives. Indian government's continued push to establish India as a global electronics manufacturing hub is driving long-term growth opportunities across the value chain. In particular, efforts to build a domestic semiconductor ecosystem bode well for KAYNES, which stands out as one of the few players approved for the OSAT segment. At the same time, DIXON continues to expand beyond smartphones, leveraging its scale and capabilities to enter high-potential segments such as display modules and IT hardware (laptops, tablets, etc.). On the consumer side, sustained demand for cooling products amid a hot summer outlook is expected to drive over 25% growth in RAC revenues for FY25. Industry players are optimistic about achieving 20%+ RAC revenue CAGR over the next 3–5 years, creating a favorable backdrop for companies like PGEL and AMBER. Meanwhile, ELIN is also set to benefit from positive structural shifts — with the end of its exclusivity with Signify in LED products and a revival in demand for small domestic appliances; we see potential for margin improvement and valuation re-rating.

Our Preferred Picks: DIXON (BUY), KAYNES (HOLD), AMBER (BUY) and SYRMA (BUY)

Krisha Zaveri krishazaveri@systematixgroup.in +91 22 6704 8023

Systematix Research is also available on Bloomberg SSSL <Go>, Thomson & Reuters

Exhibit 1: EMS companies under coverage - 4QFY25 estimates and highlights (Rs mn)

AMBER	4QFY25E	3QFY25	4QFY24	YoY (%)	QoQ (%)	Comments							
Revenue	34,891	21,333	28,055	24	64	4Q is expected to be driven by increased offtake in primary RAC							
EBITDA	2,852	1,587	2,219	29	80	sales, fueled by channel filling in anticipation of a favorable summer. The electronics division is set to continue its growth trajectory, with							
EBITDA margin (%)	8.17	7.44	7.91			the company having revised its revenue guidance to 55% YoY gro							
PAT	1,404	359	947	48	291	for FY25 (vs 45% guided earlier). However, revenue and profitable from the railway segment are likely to remain subdued in 4Q,							
EPS (Rs)	42	11	28	48	291	company to clock 8% EBITDA margin, in line with its guidance.							
AVALON	4QFY25E	3QFY25	4QFY24	YoY (%)	QoQ (%)								
Revenue	3,104	2,809	2,168	43	11								
EBITDA	393	346	172	129	14	We expect AVALON to deliver 43% YoY topline growth at Rs 3.1bn, driven by the revival of US business and onboarding of new clients.							
EBITDA margin (%)	12.66	12.33	7.93			EBITDA is projected to rise sharply by 129% YoY to Rs 393mn, with							
PAT	224	240	71	217	(7)	EBITDA margin likely to expand to 12.6%, up from 7.9% during							
EPS (Rs)	3	4	1	217	(7)	4QFY24. We estimate PAT of Rs 224mn.							
DIXON	4QFY25E	3QFY25	4QFY24	YoY (%)	QoQ (%)	Comments							
Revenue	1,20,656	1,04,537	46,580	159	15								
EBITDA	4,320	3,905	1,825	137	11	We expect robust 159% YoY revenue growth to be primarily driven by a 240% YoY surge in the mobiles segment, supported by a QoQ							
EBITDA margin (%)	3.58	3.74	3.92			ramp-up in Ismartu volumes. Additionally, the refrigerator business is							
PAT	2,466	1,712	952	159	44	also poised to boost revenue. Margins in the lighting segment are expected to improve, aided by backward integration.							
EPS (Rs)	41	29	16	159	44	orpored to improve, alees 2, 220 mars integration							
ELIN	4QFY25E	3QFY25	4QFY24	YoY (%)	QoQ (%)	Comments							
Revenue	3,110	2,663	2,778	12	17	4Q is expected to be decent, with revenue growth of 12% YoY. In the							
EBITDA	147	76	124	18	94	TPW fans segment, the company expects to benefit from the addition of a top 5 customer. In the lighting segment, 2 new							
EBITDA margin (%)	4.71	2.84	4.47			customer additions are expected during 4Q. However, margins are							
PAT	55	14	35	56	296	likely to remain under pressure due to a subdued demand environment, resulting in heightened competition across lighting,							
EPS (Rs)	1	0	1	56	296	fans, and small appliances.							
KAYNES	4QFY25E	3QFY25	4QFY24	YoY (%)	QoQ (%)	Comments							
Revenue	10,639	6,612	6,373	67	61	KAYNES is projected to clock strong revenue growth in 4Q, driven by execution of smart meter orders. Gross margin expansion will likely							
EBITDA	1,752	940	952	84	86	be fueled by a surge in orders from high-margin sectors such as							
EBITDA margin (%)	16.47	14.22	14.94			industrial & EV, aerospace, medical, and automotive sec Operating leverage benefits are expected to materialize in 4Q, d the revenue pick-up in recent acquisitions. In the railways segr							
PAT	1,188	665	813	46	79								
EPS (Rs)	19	10	13	46	79	increased order inflows will likely contribute to growth in 4Q, desp the slow offtake.							
PGEL	4QFY25E	3QFY25	4QFY24	YoY (%)	QoQ (%)	Comments							
Revenue	16,537	9,677	10,766	54	71	4Q is expected to be strong, led by 100% YoY growth in RACs, driven							
EBITDA	1,946	852	1,165	67	128	by channel filling in anticipation of summer. Washing machines too are likely to post healthy YoY revenue growth, on a low base. In the							
EBITDA margin (%)	11.76	8.80	10.82			product business, we expect significant scale-up from clients onboarded over the last two years, contributing to market share							
PAT	1,483	395	696	113	275	gains. While we see gross margin declining QoQ due to higher							
EPS (Rs)	5	1	2	113	275	contribution from RACs, net margin may expand, aided by the receipt of a Rs 300mn PLI benefit during the quarter.							
SYRMA	4QFY25E	3QFY25	4QFY24	YoY (%)	QoQ (%)	Comments							
Revenue	14,580	8,692	11,341	29	68	SYRMA is likely to see a 29% YoY revenue expansion at Rs 14.6bn.							
EBITDA	1,468	791	737	99	86	EBITDA could increase 99% YoY to Rs 1.4bn. EBITDA margin is							
EBITDA margin (%)	10.07	9.10	6.50			expected to expand to 10.1%, up from 6.5% in 4QFY24, as the contribution from lower margin consumer business continues to							
PAT	870	488	349	149	78	decline. This margin improvement positions the company to exceed							
EPS (Rs)	5	3	2	149	78	its guidance of 7% EBITDA margin.							

Source: Company, Systematix Institutional Research

Exhibit 2: Valuation table

	M-cap	CMP _		ТР	Upside	T PE		P/E (x)	RoIC (%)				
	(Rs bn)	15-Apr	Reco	кесо	(Rs)	(Rs) (%)	Rs) (%)	(27E x)	FY25E	FY26E	FY27E	FY25E	FY27E
AMBER	233	6,880	BUY	8,052	17	43	87	59	37	17	23		
AVALON	55	830	HOLD	827	(0)	38	89	52	38	16	24		
DIXON	893	14,930	BUY	17,587	18	55	95	68	47	71	142		
ELIN	7	137	BUY	167	22	16	37	20	13	6	13		
KAYNES	353	5,520	HOLD	5,517	(0)	60	119	91	60	24	19		
PGEL	248	955	HOLD	981	3	50	85	64	49	31	34		
SYRMA	87	490	BUY	713	46	30	46	32	21	14	22		

	EPS (Rs)			CAGR (%) (FY20-24)			CAGR (%) (FY24-27E)			RoE (%)		RoCE (%)		EV/EBITDA (x)	
	FY25E	FY26E	FY27E	Rev	EBITDA	PAT	Rev	EBITDA	PAT	FY25E	FY27E	FY25E	FY27E	FY25E	FY27E
AMBER	79	117	187	14	12	(4)	31	38	68	11	19	15	21	32	19
AVALON	9	16	22	8	(1)	25	31	56	73	10	17	13	21	51	23
DIXON	157	220	320	42	33	32	66	61	73	37	35	53	55	59	29
ELIN	4	7	10	7	(8)	(16)	14	31	53	3	9	6	12	13	7
KAYNES	46	61	92	49	57	110	54	60	48	11	16	16	18	84	36
PGEL	11	15	20	44	60	168	36	41	56	22	23	29	32	54	34
SYRMA	11	15	24	38	10	3	39	54	58	11	18	14	22	27	13

Source: Company, Systematix Institutional Research

DISCLOSURES/APPENDIX

I. ANALYST CERTIFICATION

I, Krisha Zaveri; hereby certify that (1) views expressed in this research report accurately reflect my/our personal views about any or all of the subject securities or issuers referred to in this research report, (2) no part of my/our compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in this research report by Systematix Shares and Stocks (India) Limited (SSSIL) or its group/associate companies, (3) reasonable care is taken to achieve and maintain independence and objectivity in making any recommendations.

Disclosure of Interest Statement	Update
Analyst holding in the stock	No
Served as an officer, director or employee	No

- II. ISSUER SPECIFIC REGULATORY DISCLOSURES, unless specifically mentioned in point no. 9 below:
 - 1. The research analyst(s), SSSIL, associates or relatives do not have any financial interest in the company(ies) covered in this report.
 - 2. The research analyst(s), SSSIL, associates or relatives collectively do not hold more than 1% of the securities of the company(ies) covered in this report as of the end of the month immediately preceding the distribution of the research report.
 - 3. The research analyst(s), SSSIL, associates or relatives did not have any other material conflict of interest at the time of publication of this research report.
 - 4. The research analyst, SSSIL and its associates have not received compensation for investment banking or merchant banking or brokerage services or any other products or services from the company(ies) covered in this report in the past twelve months.
 - 5. The research analyst, SSSIL or its associates have not managed or co-managed a private or public offering of securities for the company(ies) covered in this report in the previous twelve months.
 - 6. SSSIL or its associates have not received compensation or other benefits from the company(ies) covered in this report or from any third party in connection with this research report.
 - 7. The research analyst has not served as an officer, director or employee of the company(ies) covered in this research report.
 - 8. The research analyst and SSSIL have not been engaged in market making activity for the company(ies) covered in this research report.
 - 9. Details of SSSIL, research analyst and its associates pertaining to the companies covered in this research report:

Sr. No.	Particulars	Yes / No.
1	Whether compensation was received from the company(ies) covered in the research report in the past 12 months for investment banking transaction by SSSIL.	No
2	Whether research analyst, SSSIL or its associates and relatives collectively hold more than 1% of the company(ies) covered in the research report.	No
3	Whether compensation has been received by SSSIL or its associates from the company(ies) covered in the research report.	No
4	Whether SSSIL or its affiliates have managed or co-managed a private or public offering of securities for the company(ies) covered in the research report in the previous twelve months.	No
5	Whether research analyst, SSSIL or associates have received compensation for investment banking or merchant banking or brokerage services or any other products or services from the company(ies) covered in the research report in the last twelve months.	No

10. There is no material disciplinary action taken by any regulatory authority that impacts the equity research analysis activities.

STOCK RATINGS

BUY (B): The stock's total return is expected to exceed 15% over the next 12 months.

HOLD (H): The stock's total return is expected to be within -15% to +15% over the next 12 months.

SELL (S): The stock's total return is expected to give negative returns of more than 15% over the next 12 months.

NOT RATED (NR): The analyst has no recommendation on the stock under review.

INDUSTRY VIEWS

ATTRACTIVE (AT): Fundamentals/valuations of the sector are expected to be attractive over the next 12-18 months.

NEUTRAL (NL): Fundamentals/valuations of the sector are expected to neither improve nor deteriorate over the next 12-18 months.

CAUTIOUS (CS): Fundamentals/valuations of the sector are expected to deteriorate over the next 12-18 months.

III. DISCLAIMER

The information and opinions contained herein have been compiled or arrived at based on the information obtained in good faith from sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy completeness or correctness.

This document is for information purposes only. This report is based on information that we consider reliable; we do not represent that it is accurate or complete and one should exercise due caution while acting on it. Description of any company(ies) or its/their securities mentioned herein are not complete and this document is not and should not be construed as an offer or solicitation of an offer to buy or sell any securities or other financial instruments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. All opinions, projections and estimates constitute the judgment of the author as on the date of the report and these, plus any other information contained in the report, are subject to change without notice. Prices and availability of financial instruments are also subject to change without notice. This report is intended for distribution to institutional investors.

This report is not directed to or intended for display, downloading, printing, reproducing or for distribution to or use by, any person or entity that is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, reproduction, availability or use would be contrary to law or regulation or what would subject to SSSIL or its affiliates to any registration or licensing requirement within such jurisdiction. If this report is inadvertently sent or has reached any individual in such country, especially USA, the same may be ignored and brought to the attention of the sender. Neither this document nor any copy of it may be taken or transmitted into the United States (to U.S. persons), Canada, or Japan or distributed, directly or indirectly, in the United States or Canada or distributed or redistributed in Japan or to any resident thereof. Any unauthorized use, duplication,

redistribution or disclosure of this report including, but not limited to, redistribution by electronic mail, posting of the report on a website or page, and/or providing to a third party a link, is prohibited by law and will result in prosecution. The information contained in the report is intended solely for the recipient and may not be further distributed by the recipient to any third party.

SSSIL generally prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, SSSIL generally prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that they cover. Our salespeople, traders, and other professionals or affiliates may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein. Our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. The views expressed in this research report reflect the personal views of the analyst(s) about the subject securities or issues and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report. The compensation of the analyst who prepared this document is determined exclusively by SSSIL; however, compensation may relate to the revenues of the Systematix Group as a whole, of which investment banking, sales and trading are a part. Research analysts and sales persons of SSSIL may provide important inputs to its affiliated company(ies).

Foreign currencies denominated securities, wherever mentioned, are subject to exchange rate fluctuations which could have an adverse effect on their value or price or the income derived from them. In addition, investors in securities such as ADRs, the values of which are influenced by foreign currencies, effectively assume currency risk. SSSIL, its directors, analysts or employees do not take any responsibility, financial or otherwise, of the losses or the damages sustained due to the investments made or any action taken on the basis of this report including but not restricted to fluctuation in the prices of shares and bonds, changes in the currency rates, diminution in the NAVs, reduction in the dividend or income, etc.

SSSIL and its affiliates, officers, directors, and employees subject to the information given in the disclosures may: (a) from time to time, have long or short positions in, and buy or sell, the securities thereof, of company (ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation (financial interest) or act as a market maker in the financial instruments of the company (ies) discussed herein or act as advisor or lender / borrower to such company (ies) or have other potential material conflict of interest with respect to any recommendation and related information and opinions. The views expressed are those of the analyst and the company may or may not subscribe to the views expressed therein.

SSSIL, its affiliates and any third party involved in, or related to, computing or compiling the information hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any of this information. Without limiting any of the foregoing, in no event shall SSSIL, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind. The company accepts no liability whatsoever for the actions of third parties. The report may provide the addresses of, or contain hyperlinks to, websites. Except to the extent to which the report refers to website material of the company, the company has not reviewed the linked site. Accessing such website or following such link through the report or the website of the company shall be at your own risk and the company shall have no liability arising out of, or in connection with, any such referenced website.

SSSIL will not be liable for any delay or any other interruption which may occur in presenting the data due to any technical glitch to present the data. In no event shall SSSIL be liable for any damages, including without limitation, direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by SSSIL through this presentation.

SSSIL or any of its other group companies or associates will not be responsible for any decisions taken on the basis of this report. Investors are advised to consult their investment and tax consultants before taking any investment decisions based on this report.

Registration granted by SEBI to SSSIL and certification from NISM to the analyst in no way guarantee performance of SSSIL or to provide any assurance of returns to investors.





Systematix Shares and Stocks (India) Limited:

Registered and Corporate address: The Capital, A-wing, No. 603 - 606, 6th Floor, Plot No. C-70, G Block, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051 Tel no. 022-66198000/40358000 Fax no. 022-66198029/40358029 Email id contactus@systematixgroup.in. Visit us at: www.systematixgroup.in Details of Compliance officer: Ms Nipa Savla, Compliance officer Tel no. 022-66198092/4035808092 Email id compliance@systematixgroup.in

Details of Email id grievance redressal cell: grievance@systematixgroup.in

Details of Registration: CIN - U65993MH1995PLC268414 | BSE SEBI Reg. No.: INZ000171134 (Member Code: 182) | NSE SEBI Reg. No.: INZ000171134 (Member Code: 11327) | MCX SEBI Reg. No.: INZ000171134 (Member Code: 56625) | NCDEX SEBI Reg. No.: INZ000171134 (Member Code: 1281) | Depository Participant SEBI Reg. No.: IN-DP-480-2020 (DP Id: 12034600) | PMS SEBI Reg. No.: INP000002692 | Research Analyst SEBI Reg. No.: INH200000840 | AMFI: ARN - 64917